|
|
 |
|
Viewing report
|
|
|
|
Systems Biology in Biotech and Pharma: A New Paradigm for Innovation
Biopharm Knowledge Publishing, July 2009
Growth in the pharmaceutical market has slowed – almost to a standstill. One reason is that governments and other payers are cutting costs in a faltering world economy.
But a more fundamental problem is the failure of major companies to discover, develop and market new drugs. Major drugs losing patent protection or being withdrawn from the market are simply not being replaced by new therapies – the pharmaceutical market model is no longer functioning effectively and most pharmaceutical companies are failing to produce the innovation needed for success.
This new report looks at a vital strategy which can bring innovation to a market in need of new ideas and new products - Systems Biology.
Systems Biology employs a rational approach, via a mix of analytical and systemic routes, to delineate the emerging properties of biological networks. It aims to explain and predict, quantitatively, molecular, cellular, tissue, organ and whole-body processes. By using multi-scale models in silico, Systems Biology is expected to bring numerous benefits to pharmaceutical discovery and development as the properties of a system can be studied over a wide range of length and time scales.
Systems Biology can reduce the number of compounds that need to be synthesised in discovery by using refined algorithms to weed out compounds with poor pharmacokinetic of toxicology profiles. And it will save time and money by selecting the drugs which are more likely to succeed in clinical development.
This new 200 page report is written by industry and academic expert Dr Ales Prokop, one of the leading researchers in Systems Biology. It will enable you to:
- Understand the nature and processes involved in Systems Biology
- See how its benefits relate to pharmaceutical innovation
- Delineate the costs and cost savings involved
- Understand why Systems Biology improves on current approaches to drug discovery
- Relate Systems Biology to advances in genetic profiling and personalised medicine
Contents include:
- Tools and lead optimisation
- Virtual chemistry screening
- Lead discovery and molecular interactions
- In silico screening
- Computational Systems Biology in cell biology
- Pharmacology and pharmacokinetics
- Formulation and production
- Model-based drug development
Systems Biology is essential reading for corporate management and those in product, process and analytical discovery and development, product quality and characterisation, R&D, and regulatory affairs. It is aimed at biotech, big pharma, producers of biosimilars, contract manufacturers, providers of analytical services, and clinical research organizations. This report gives an authoritative, detailed and clear explanation of the issues surrounding Systems Biology, its implications for the market and for the biotech and pharmaceutical industries.
Customers who bought this item also bought
Systems Biology - Key to Unlocking the Value within the Omics Revolution
Bioinformatics: Players; Problems; and Processes in Computational Biology (Technical Insights)
Business Intelligence Success Factors: Tools for Aligning Your Business in the Global Economy
Translational Medicine in Biopharmaceutical R&D: Enabling R&D Optimization and Early Detection of Potential Failures
Nanotechnology for Drug Discovery and Drug Design
Sustainable Design: The Science of Sustainability and Green Engineering
Cell-Based Assays for Drug Discovery
Novel therapeutics and future R&D
COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease
Pipeline Insight: Hematological Malignancies - Targeted Treatments And Immunotherapy Infuse New Blood
Biotechnology Reagents - Global Strategic Business Report
Addressing Pharma’s R&D Productivity Crisis: Technological and Strategic Initiatives to Improve Core Drug Discovery Capabilities
|
|
|
|
